PPRT-211(PPRT-211) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

valerian extract

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病

在研适应症-

非在研适应症

入睡和睡眠障碍

原研机构

PharmaPrint, Inc.

在研机构-

非在研机构

PharmaPrint, Inc.

权益机构-

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 PPRT-211 相关的临床结果

登录后查看更多信息

100 项与 PPRT-211 相关的转化医学

登录后查看更多信息

100 项与 PPRT-211 相关的专利（医药）

登录后查看更多信息

2

项与 PPRT-211 相关的文献（医药）

Pharmazie

Application of content uniformity test to tablet preparations

作者: Darbai, M. Jusztin ; Hadady, K. Kovacs ; Kovacs, I.

Three com. tablet products made from phenoxymethylpenicillin [87-08-1], valerian extract plus phenobarbital [50-06-6], and ascorbic acid [50-81-7] plus FeSO₄ were examined by the Content Uniformity Test of the USP XIX.These products met the active content requirement.Anal. results of all the tablets are tabulated.Use of the Content Uniformity Test is justified.

Anesteziologiia i reanimatologiia

[Preoperative psychopharmacological correction in women with focal breast diseases].

Article

作者: Ustimov, D Iu

The paper presents the results of a study dealing with the choice of an agent to correct the psychoemotional state in women with dyshormonal focal breast diseases (DFBD). The correction involved dimedrol, valerian extract, Novopassite, diazepam, phenazepam, amitryptiline, coaxil, grandaxine, alprozam (Xanax), or atarax. To assess the results, clinical, psychopathological, clinicopsychological, anamnestic, and experimental psychological studies were used. The use of alprozam and atarax yielded the best results of correcting the psychoemotional state in women with DFBD, by producing minimum adverse reactions.

100 项与 PPRT-211 相关的药物交易

登录后查看更多信息